Amyloid Cardiomyopathy

Amyloid cardiomyopathy is a major cause of morbidity and mortality in various types of systemic amyloidoses. Diagnosis is often delayed due to the rarity of disease, nonspecific presenting symptoms, and inability to recognize early signs of amyloid heart disease. Management and prognosis depends upon the type of amyloidogenic protein. Chemotherapy is used to treat immunoglobulin-related amyloidosis. Liver transplantation is used for the familial transthyretin amyloidoses in select patients. Novel trials utilizing small interfering RNA for the treatment of transthyretin amyloid cardiomyopathies and amyloid protein stabilizers are ongoing. Supportive care forms the cornerstone of management.